Vaccines are an important part of human welfare and healthcare globally. This has been demonstrated with the on-going Covid-19 pandemic, which has impacted every individual in some way. There is now a clear need to develop, validate and manufacture vaccines in months rather than years. Promising technologies such as mRNA vaccines have shown great efficacy in targeting infectious diseases. However, in most cases, a bottleneck remains in encapsulating the biotherapeutic for safe and effective delivery.
Liposomes or lipid nanoparticles (LNP) are attractive delivery vehicles for biotherapeutics since they resemble the structure of human biological membranes. Although there are liposomal vaccines currently on the market, the process to develop a suitable formulation for a specific biotherapeutic can be laborious, costly and time-consuming. The development pipeline is further exacerbated by the lack of automation technology available for building formulation libraries for subsequent screening. Dolomite’s new Automated Nanoparticle System (ANP) tackles this.
Read more about the microfluidic methods to accelerate vaccine R&D and production which reduce lead times, increase efficiency and quality, and reduce development costs.
This webinar will introduce Dolomite’s Automated Nanoparticle System, a next-generation system dedicated to protocol development and production of a wide range of nanoparticle types including liposomes, lipid nanoparticles and more. Tailored and scalable, it facilitates library generation for formulation screening allowing you to progress through the protocol development pipeline without the need to change your entire system.